{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:12:02Z","timestamp":1783836722749,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.transci.2021.103303","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T11:12:35Z","timestamp":1635592355000},"page":"103303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8134-3376","authenticated-orcid":false,"given":"Kevin Y.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler G.","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-6790","authenticated-orcid":false,"given":"J. Ryan","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice D.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Grgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-0990","authenticated-orcid":false,"given":"Marcie","family":"Riches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-6613","authenticated-orcid":false,"given":"Jonathan R.","family":"Ptachcinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.transci.2021.103303_bib0005","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.transci.2021.103303_bib0010","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2021.103303_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","article-title":"Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.transci.2021.103303_bib0020","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2012.74","article-title":"Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization","volume":"47","author":"Chen","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transci.2021.103303_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jca.21256","article-title":"An algorithm for utilizing peripheral blood CD34 count as a predictor of the need for plerixafor in autologous stem cell mobilization-cost-effectiveness analysis: Utilization of CD34 Count","volume":"28","author":"Abusin","year":"2013","journal-title":"J Clin Apheresis"},{"issue":"1","key":"10.1016\/j.transci.2021.103303_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"Micallef","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.transci.2021.103303_bib0035","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.transci.2021.103303_bib0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to g-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transci.2021.103303_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2010.170","article-title":"Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103303_bib0050","article-title":"Impact of plerixafor use at different peripheral blood CD34+ thresholds on autologous stem cell collection in patients with multiple myeloma","author":"Shah","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221003037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221003037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:55:01Z","timestamp":1761468901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050221003037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1473050221003037"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2021.103303","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2021.103303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103303"}}